A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Open to people ages 18-79

-

• Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m²).
• Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria.
• Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS.
• SOD1-ALS (Cohorts 2 and 3 only): Confirmed pathogenic SOD1 mutation, with negative testing for other genetic mutations associated with familial ALS.
• Any polymorphism or mutation in the coding region will require additional review by the Sponsor to determine compatibility with the study intervention.
• Baseline ALSFRS-R ≥ 24.
• ALS disease duration ≤ 42 months.

-

• Previous treatment for ALS with cellular or gene therapies.
• Any investigational medication or treatment (for ALS or other condition).

Note: Other protocol-defined inclusion/exclusion criteria may apply.